The oncofetal alpha -fetoprotein ( AFP ) is reexpressed in the majority of hepatocellular carcinomas and may be used as a target molecule for an immunotherapy or prophylaxis against this tumor. We investigated the potential of DNA vaccination with AFPexpressing plasmid DNA to induce an immune response against AFP -expressing tumor cells in DBA / 2 mice. 62.5% of mice vaccinated with AFP -expressing plasmid DNA, rejected subcutaneous syngeneic AFP -expressing P815 tumors, whereas only 16.7% of mice vaccinated with control plasmid rejected these tumor cells ( P = .03 ). Mean survival of mice after challenge with subcutaneous AFP -expressing tumor cells was prolonged for 8 days in mice vaccinated with AFP -expressing DNA ( 35 days ) compared to mice vaccinated with control plasmid ( 27 days ). To rule out possible autoimmune reactions against regenerating liver, which also reexpresses AFP, we evaluated the influence of AFP -specific DNA vaccination on liver regeneration in DBA / 2 mice. Histologic quantification of proliferating hepatocytes and of the amount of necrotic liver tissue in carbon tetrachloride -damaged liver did not reveal statistically significant differences in mice vaccinated with AFP -expressing plasmid compared to control mice. These data suggest that AFP -specific DNA vaccination represents a useful tool to inhibit growth of AFP -expressing tumors in mice that does not affect liver regeneration.
H epatocellular carcinoma (HCC ) is a common malignancy with a very poor prognosis. Only a minority of patients are eligible for surgical therapies due to advanced tumors or extrahepatic disease at primary diagnosis. 1, 2 Therefore, novel strategies to prevent proliferation of malignant cells are urgently needed. A promising approach may be the prophylactic vaccination directed against a tumor-associated antigen (TAA ). This approach has been successful in mouse models for several tumor-associated self -antigens such as the tyrosinase -related protein (TRP )-2 in murine melanoma 3, 4 or the model antigens polymorphic endothelial mucin (MUC ) -1 and P815A. 5, 6 A colon cancer -specific DNA vaccination directed against the carcinoembryonic antigen ( CEA ) is in Phase I clinical trial. 7 One possible target for an HCC -specific vaccination is the oncofetal alpha -fetoprotein (AFP ). It is a 70 -to 80-kDA secretory protein that is heterogenously glycosylated. 8 In the fetus, AFP is likely to function as a transporter of metabolites such as fatty acids. 9 AFP is usually expressed in high concentrations in the fetal liver, the gastrointestinal tract, and the yolk sack and transcriptionally down -regulated after birth. AFP is frequently reexpressed in HCCs and therefore used as a diagnostic marker for this tumor. 10 It has been postulated that HCCs develop from mature hepatocytes, which regain the ability to proliferate and harbor an expression pattern similar to that of fetal liver cells. 11 Yet it is not clear whether AFP expression influences tumor growth in vivo, but it has been shown in vitro that AFP promotes cell proliferation of hepatoma cell lines. 12 However, not only preneoplasia, but also liver regeneration, is characterized by the presence of dedifferentiated hepatocytes that reexpress AFP. 13 Liver regeneration is therefore accompanied by an increase of AFP serum levels in humans as well as in mice. 14 A prerequisite for the induction of an AFP -specific immune response is the existence of cytotoxic T lymphocytes (CTL ), which recognize AFP -derived peptides in context of MHC class I molecules. There is strong evidence that AFP -specific T lymphocytes that have escaped deletional tolerance mechanisms exist in humans and could be activated upon immunization. We were able to detect AFP -specific CD4 -and CD8 -positive lymphocytes by in vitro stimulation of peripheral blood lymphocytes (PBLs ) with human AFP in healthy volunteers and cirrhotic patients with or without HCC. Others identified an AFP -derived peptide that in vitro induces CD8 -positive CTLs in PBLs from healthy individuals. 15 AFP -reactive antibodies were also shown to be present in sera of patients with various liver diseases. 16 In mice, it could be demonstrated that AFPspecific vaccination induces an AFP -specific cytotoxic tumor-eliminating immune response. 17 , 18 Here we demonstrate that vaccination with AFP -expressing plasmid DNA impairs growth of subcutaneous AFP -expressing tumor cells in mice. Evidence is provided that this vaccination approach does not impair chemically induced liver regeneration in this mouse model.
Materials and methods

Plasmids
To generate the AFP -encoding vaccination plasmid pCI -AFP, the full -length cDNA of murine AFP was cloned into the eukaryotic expression plasmid pCI (Promega, Madison, WI ). Basepairs ( bp) 720 -2064, including the poly A region of the AFP -cDNA, were excised from the AFP subclone -containing plasmid, pAF6.
19 Bp 1 -721 of the AFP -cDNA were amplified from the murine, AFPexpressing hepatoma cell line Hepa 1-6 (ATCC, Manassas, VA ) by reverse transcriptase polymerase chain reaction ( RT-PCR ). The full -length AFP -cDNA was cloned into the neomycin (neo ) resistance-conferring plasmid, BMGneo. 20 The cytokine-encoding expression plasmids, pCI-2/ granulocyte -macrophage colony -stimulating factor (GM -CSF ), pCI -2 /p35, and pCI-2/ p40 used for coimmunization of mice have been provided by J Reimann.
Cell lines and mouse strains
The H -2 d -positive murine mastocytoma cell line P815 ( TIB -64; ATCC ) was cultivated in RPMI 1640 Glutamax 2 supplemented with 5% fetal calf serum (FCS ) ( vol /vol ) and 50 M 2-mercaptoethanol (2 -ME ) (Life Technologies ). A concentration of 400 g /mL G418 ( Biochrom, Berlin, Germany ) was added to this medium to maintain P815 transfectants, P815 -neo and P815 -neo -AFP. The human cervix carcinoma cell line, HeLa (CCL -2; ATCC ), and the AFP -expressing murine hepatoma cell line, Hepa 1 -6 ( CRL -1830; ATCC ), were kept in DMEM Glutamax 2 supplemented with 10% FCS ( vol /vol ) (Life Technologies , Rockville, MD). The H -2 d -positive inbred mouse strain DBA / 2 was purchased from Charles River (Sulzfeld, Germany ) and bred and kept under specified pathogen -free conditions. BALB /cJHanHsd-scid mice were purchased from Harlan Winkelmann (Borchen, Germany ).
Transient transfections of HeLa cells and stable transfections of P815 cells
HeLa cells were transiently transfected with pCI -AFP or mock -transfected by electroporation using EasyjecT Plus ( Equibio, Middlesex, UK ). P815 cells were stably transfected with BMG -neo-AFP or BMG -neo by electroporation. Stably transfected P815 cells were selected by increasing concentrations ( up to 1 mg /mL ) of G418. The resulting P815-neo and P815 -neo -AFP cells were cloned in 96-well plates by limiting dilution to obtain single cell clones. Tumor challenge experiments were performed twice using 2 of 10 different AFP -expressing P815 clones.
Detection of AFP expression
A total of 2 -5Â10 6 cells were metabolically labelled with 30 Ci of 35 S -methionine for 1 hour at 378C in methioninefree RPMI 1640 (Sigma Aldrich, St. Louis, MO ). The supernatant was collected and filled up to a volume of 1 mL with lysis buffer ( Tris -buffered saline/ 1% Nonidet P -40) containing protease inhibitors (Sigma Aldrich). Cells were lysed in 1 mL of lysis buffer. Lysates and supernatants were precleared and proteins immunoprecipitated using a rabbit anti-AFP antiserum ( ICN, Costa Mesa, CA ) coupled to 10 L of protein A Sepharose (Bio -Rad, Hercules, CA ). Precipitated proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis ( SDS -PAGE ) followed by autoradiography.
Intramuscular ( i.m. ) and intradermal ( i.d. ) vaccination of mice
For i.m. DNA vaccination, plasmid DNA was purified by Qiagen plasmid Giga kit using Qiagen tips 10000 ( Qiagen, Hilden, Germany ) and solubilized in PBS to a concentration of 1 g/L. DNA injection was preceded by injection of 50 L of 62.5 M cardiotoxin ( Latoxan, Valence, France) solubilized in PBS into each musculus tibialis. Four days later, 50 g of DNA was injected into each musculus tibialis. The i.m. injections were performed under anesthesia. DNAloaded tubes for i.d. DNA vaccination were prepared according to the manufacturer's guidelines (Bio -Rad ), achieving a loading rate of 0.5 g of gold (particles of 1 m diameter ) to 1 g of DNA per injection. The gold particles were injected with a pressure of 200 psi using a Helium -driven Gene Gun ( Bio -Rad ).
Induction of liver regeneration, in vivo bromodeoxyuridine ( BrdU ) labelling
To induce a reversible necrotic liver damage in mice, 80 L/ 10 g body weight carbon tetrachloride diluted 1:10 in olive oil was injected intraperitoneally (i.p. ). To label proliferating hepatocytes in vivo, 75 mg /kg body weight BrdU (Sigma Aldrich ) was injected i.p. 2 hours prior to sacrificing the animals.
Immunohistochemical detection of BrdU and AFP
Liver tissue samples and samples of subcutaneous P815 tumors were fixed in PBS -buffered 4% ( wt/ vol ) paraformaldehyde (pH 7.4 ). Deparaffinized liver sections were boiled in citrate buffer (pH 6.0) and proteolytically digested in protease VIII (Sigma Aldrich ). Endogenous peroxidase activity was blocked by 3% hydrogen peroxide. For detection of BrdU, DNA was denatured using formamide. Unspecific binding was reduced using swine normal serum ( Dako, Glostrup, Denmark ) diluted 1:5 in PBS. BrdU was detected using a mouse monoclonal anti -BrdU antibody ( clone BU 20a; Dako ) and the commercially available LSAB Plus 2 Kit (Dako ). AFP expression was detected using a 1:100 diluted rabbit anti -AFP antiserum ( ICN ) and a 1:250 diluted goat anti -rabbit HRP -conjugated secondary antibody (Dianova, Hamburg, Germany ). 3,3 0 -Diaminobenzidine ( Dako ) was used as peroxidase substrate. Nuclei were stained with hematoxylin, and dehydrated sections were mounted in Pertex 2 .
Quantification of liver regeneration
Liver regeneration was quantified by counting of BrdUlabelled hepatocytes in 10,000 healthy hepatocytes at Â400 magnification on BrdU -stained liver sections. The extent of necrotic liver tissue was determined on H&E -stained sections in 20 power fields at a magnification of Â400 by the point -counting stereological method described by Weibel 21 using a square point lattice system consisting of 121 points. The mean numbers of BrdU -positive hepatocytes and the mean percentages of necrotic liver tissue were determined for each group and statistically compared.
AFP -specific restimulation of mouse lymphocytes
Splenocytes were separated by lysis of erythrocytes and resuspended at a concentration of 3Â10 7 lymphocytes per 10 mL in RPMI 1640 supplemented with 10% FCS, 50 M 2 -ME, 25 mM HEPES, 10% T-Stim 2 (Becton Dickinson, Franklin Lakes, NJ ), and 10 U /mL interleukin (IL )-2 ( restimulation medium ). Either 1 -5Â10 6 lethally irradiated P815 -neo-AFP cells or bone marrow -derived dendritic cells (DC ) pulsed with AFP -containing Â5 concentrated tissue culture supernatant of Hepa 1 -6 cells were added as AFP -presenting stimulator cells. DCs were prepared as previously described. 22 Effector cells and stimulator cells were cocultivated for 5-21 days.
51
Chromium release assay Stably AFP -expressing P815 cells were used as target cells and labelled at a concentration of 2Â10 6 cells per 200 L of restimulation medium with 100 Ci of Na 2 51 CrO 4 ( Hartmann, Giessen, Germany ) for 90 minutes. Labelled cells were washed three times with PBS, and 5Â10 3 target cells were incubated with restimulated effector cells in effector / target cell ratios of 100:1, 50:1, 25:1, 42.5:1. Four to six hours later, 51 Cr release was measured using a TopCount NXT (Packard, Meriden, CT ) and AFP -specific lysis was calculated as follows: [( experimental cpm )À (spontaneous cpm )/( total cpm )À (spontaneous cpm )Â100 ].
Induction of subcutaneous tumors
A total of 10 4 -10 6 P815-neo and P815 -neo -AFP cells, washed three times in PBS and resolved in 100 L of PBS, were injected into the shaved flank of DBA /2 mice and scid mice. Mice were then monitored three times per week for tumor growth. Four weeks later, tumors were counted and animals were sacrificed. To determine survival of animals after tumor challenge, mean tumor diameters were measured and mice were sacrificed if the mean tumor diameter exceeded 12.5 mm, or if the tumors became ulcerated. Tumor challenge experiments were repeated at least once.
Statistical analysis
As the data are not distributed normally, only nonparametric methods were used. For descriptive statistics, means and standard errors of the mean are noted. Comparisons of continuous parameters between groups were performed using the Mann -Whitney U test. Contingency tables were tested for statistical significance using one-sided Fisher's exact test. Survival analysis was performed using KaplanMeier method and log -rank test. A P value of less than .05 was considered significant.
Results
Generation and testing of an AFP -encoding vaccination plasmid
The complete murine AFP -cDNA sequence was cloned into the eukaryotic expression plasmid pCI in which the AFP -cDNA is transcribed under the control of the cytomegalovirus promotor /enhancer. To demonstrate the expression of pCI -AFP in eukaryotic cells, HeLa cells were transiently transfected with pCI-AFP. Figure 1A shows that AFP could be precipitated using an anti -AFP antiserum from cell lysates and, to a lesser extent, from supernatants of HeLa cells that have been transiently transfected with pCI -AFP. No AFP expression could be detected in mock -transfected HeLa cells. As a positive control AFP was precipitated from lysate and supernatant of the murine AFP -expressing hepatoma cell line Hepa.
-6
Generation of an AFP -expressing syngeneic tumor cell line for tumor challenge experiments in DBA / 2 mice For induction of AFP -expressing subcutaneous tumor, it was necessary to stably transfect P815 cells with an AFP expression plasmid. P815 cells are syngeneic to DBA /2 mice and known to be tumorigenic. 23 For that purpose, we cloned the AFP -cDNA into the neo -resistance -conferring BMG -neo -plasmid. P815 cells were either transfected with BMG -neo (P815-neo) or BMG -neo-AFP ( P815-neo -AFP ). AFP expression in P815 -neo -AFP and P815-neo single cell clones was examined by immunoprecipitation of AFP from cell lysates of 35 S -methionine -labelled cells. Figure 1B shows that BMG -neo -AFP -transfected P815 cells (P815 -neo -AFP ) express AFP, whereas BMG -neotransfected P815 -neo cells do not express AFP. Immunoprecipitation of AFP from tissue culture supernatants showed that AFP is secreted from the P815 -neo -AFP cells ( data not shown ).
AFP -expressing and AFP -negative P815 cells were used to induce subcutaneously growing tumors in DBA / 2 mice. Injection of 10 4 tumor cells was sufficient to cause reproducible tumor growth in 100% of animals within 4 weeks; injection of 10 6 cells caused tumor growth after 10 days. AFP expression could be detected immunohistochemically in tumors derived from P815 -neo -AFP cells.
Tumors derived from P815 -neo cells did not express AFP ( data not shown ).
AFP -specific DNA vaccination impairs growth of subcutaneous AFP -expressing tumor cells in DBA / 2 mice DBA / 2 mice were i.m. vaccinated four times with either the AFP -expressing plasmid, pCI -AFP (groups I and II ), or control plasmid, pCI (groups III and IV ). Ten days after the last immunization, mice were challenged with 10 4 AFPpositive (groups I and III ) or AFP -negative P815 cells ( groups II and IV ). In a second set of experiments, mice were challenged with a high dose of tumor cells. Survival of mice vaccinated with AFP -expressing or control plasmid was investigated after challenge with 10 6 AFP -expressing or AFP -negative P815 cells. In this experimental setting, all animals ( groups I -IV ) developed tumors 10 days after tumor cell injection. These tumors were partially rejected within the next 15 days. Animals were sacrificed if tumors reached mean tumor diameters >12.5 mm. Figure 3 shows the percentages of animals surviving tumor challenge over a period of 5 weeks. All mice vaccinated with AFP -expressing plasmid DNA survived challenge with AFP -expressing tumor cells up to [ 35 ] S -methionine. Proteins from supernatants ( SN ) and cell lysates ( L ) were immunoprecipitated with an anti -AFP antiserum. B: P815 cells were stably transfected with either BMG -neo or BMG -neo -AFP. P815 -neo -and P815 -neo -AFP -cells were metabolically labelled with [ 35 ] S -methionine. Proteins from cell lysates were immunoprecipitated with an anti -AFP antiserum. A,B: As a positive control, AFP was precipitated from supernatant and lysate of Hepa 1 -6 cells. Proteins were separated by 10% SDS -PAGE, followed by autoradiography. Cancer Gene Therapy AFP -specific DNA vaccination P Hanke et al 25 days, whereas some animals already had to be killed in all control groups ( groups II -IV ). Five weeks after tumor challenge, mean survival times were calculated for each group of mice and statistically compared using the KaplanMeier method and log -rank test. Survival of mice after challenge with AFP -positive tumor cells could be prolonged for 8 days (P=.2229) by vaccination with AFP -expressing plasmid DNA (group I, n =8 ) in contrast to vaccination with control plasmid (group III, n= 8 ). Animals of group I survived challenge with AFP -expressing tumor cells for 35 days; animals of group III survived challenge with these tumor cells for only 27 days. Mean survival of animals that were vaccinated with AFP -expressing plasmid DNA was 6 days shorter (P= .0644 ) after challenge with AFP -negative tumor cells ( group II, n = 9) compared to challenge with AFP -positive tumor cells (group I ). Animals of group II showed a mean survival time of 29 days after challenge with AFP -negative tumor cells. This demonstrates AFP specificity of the observed tumor rejection after challenge with AFP -positive tumor cells. Comparison of animals that were immunized with AFP -expressing plasmid DNA and challenged with AFP -positive tumor cells ( group I ) with animals that were immunized with control plasmid and challenged with AFP -negative tumor cells (group IV, n =9) revealed a significantly shorter survival time for the latter group (P=.0109 ). Animals in group IV survived tumor challenge for only 25 days. These data demonstrate that vaccination of mice with AFP -expressing plasmid DNA prevents growth of AFP -positive tumors and supports survival of these mice. In addition, these data show that the tumor-protecting effect of the AFP -specific DNA vaccination is reproducible.
AFP -specific CTLs could not be detected in vitro
Even though DNA vaccination with AFP -expressing plasmid DNA in vivo induces an AFP -specific immune response that eliminates AFP -positive subcutaneous tumor cells, we could not reproducibly detect AFP -specific CTLs in vitro using splenocytes as effector cells. To optimize in vitro restimulation conditions, different types of stimulator cells were used and restimulation time was varied. As stimulators, we used either stably AFP -expressing P815 cells or syngeneic bone marrow -derived DCs, which had been pulsed with AFP -containing tissue culture supernatant. The duration of coculture was exceeded from 5 days up to 3 weeks to perform optimal restimulation. The coculture was supplemented with T-Stim 2 ( Becton Dickinson ) to provide optimal cytokine stimulation of AFP -specific T lymphocytes. None of these efforts leads to the detection of AFPspecific CTLs. However, in positive control experiments, we were able to detect CTL specific for the large surface antigen of hepatitis B virus (HBsAg) in mice that had been vaccinated with HBsAg -expressing plasmid DNA (data not shown). To further characterize the mechanism of AFPspecific tumor cell rejection, we repeatedly immunized 20 scid mice i.m. with AFP -expressing plasmid DNA (n =10) or control plasmid (n =10 ) and subsequently challenged these mice with 10 4 AFP -expressing P815-neo-AFP cells. Scid mice do not harbour T and B lymphocytes and could therefore be used to study tumor cell rejection mediated by innate immune responses like natural killer cells or macrophages. Neither scid mice vaccinated with AFP -expressing plasmid DNA nor mice vaccinated with control plasmid were able to reject AFP -expressing tumor cells ( data not shown ). These data show that AFP -specific tumor cell rejection seems to be mediated by mechanisms of acquired immunity, like T and B lymphocytes.
AFP -specific DNA vaccination does not interfere with liver regeneration in DBA / 2 mice
Regenerating liver also reexpresses AFP, 14 and with respect to an application of an AFP -specific vaccination approach to prevent AFP -positive HCC in humans, it is indispensable to rule out the induction of autoimmune reactions against regenerating liver. We therefore examined the influence of AFP -specific DNA vaccination on liver regeneration after chemical liver damage in DBA /2 mice. In these experiments, which address possible negative side effects of an AFP -specific vaccination, we aimed to induce an even more pronounced AFP -specific immune response as in the tumor challenge experiments. Therefore, we injected plasmid DNA i.d. using Gene Gun in addition to i.m. injection of plasmid DNA. The i.d. injection of plasmid DNA induces very potent T H 2 immune responses compared to i.m. injection, which induces T H 1 -dependent immune responses. 24 To further influence the quality of the immune response, plasmid DNA expressing the cytokines GM -CSF and IL -12 was injected simultaneously with the ( two booster immunizations ) with either AFP -expressing plus cytokine -expressing plasmid DNA or with control plasmid over a period of 2 months. Ten days after the last booster vaccination a reversible necrotic liver damage was induced by injection of carbon tetrachloride. To in vivo label proliferating cells, BrdU was injected 2 hours prior to sacrificing the mice. Liver regeneration was examined over a period of 9 days after carbon tetrachloride injection. On H&E -stained liver sections, the extent of necrotic liver tissue before and 2, 4, and 9 days after carbon tetrachloride injection was determined in groups of mice vaccinated with AFP -expressing plasmid DNA ( black bars ) or control plasmid ( white bars ). The results are depicted in Figure  4A . Over a period of 9 days, the amount of necrotic liver tissue is continuously decreasing in both groups. At day 2 after carbon tetrachloride injection, 20.8 ± 1.2% of liver tissue was necrotic in mice vaccinated with AFP -expressing plasmid DNA (n =4 ) compared to 20.0 ± 1.3% in control mice ( n= 2 ). Four days after liver damage, 17.1 ± 0.7% of the liver tissue was necrotic in AFPvaccinated mice ( n= 15 ) compared to 13.8± 1.2% in control mice (n = 10). At this time point, the necrotic areas are infiltrated by inflammatory cells. Immunohistochemical analysis showed that these infiltrates contained CD8 -positive T lymphocytes (data not shown). Nine days after damage, only 5.6 ± 0.1% in AFP -vaccinated (n = 5) and 4.5 ± 1.9% of liver tissue in control mice (n =2 ) are still altered when compared to healthy mice ( n= 4). At this time point in regeneration, the necrotic areas have been replaced by new hepatocytes, but minimal inflammatory infiltrates are still present. However, we could not detect any statistically significant differences in the extent of necrotic liver tissue at days 2, 4, and 9 after liver damage comparing AFP -vaccinated and control mice. AFP -specific DNA vaccination does not impair replacement of necrotic liver tissue by regenerated hepatocytes in DBA / 2 mice over a period of 9 days after a chemical liver damage.
On anti -BrdU -stained liver sections ( Fig 4B ) , the numbers of proliferating hepatocytes were determined in mice vaccinated with AFP -expressing plasmid DNA (black bars ) and mice vaccinated with control plasmid (white bars ) before and 2, 4, and 9 days after carbon tetrachloride injection. The bars represent mean numbers of BrdUpositive hepatocytes out of 10,000 healthy hepatocytes in each group examined. Two days after liver damage, less proliferating hepatocytes were counted in AFP -vaccinated mice (3214 ± 829, n = 4) compared to mice vaccinated with control plasmid ( 3972 ±407, n =2 ). Between days 2 and 4 of liver regeneration a decline in proliferational activity takes place. Four days after carbon tetrachloride injection, approximately one log scale less proliferating hepatocytes were counted; 151± 36 BrdU -labelled hepatocytes were counted in mice that were vaccinated with AFP -expressing plasmid (n = 15) and 233± 71 in control mice (n =10). Nine days after liver damage regeneration has been nearly completed. Only 4 ± 2 BrdU -positive hepatocytes were counted in animals vaccinated with AFP -expressing plasmid ( n =5 ) compared to 2± 1 hepatocytes in mice vaccinated with control plasmid (n = 2). These numbers are comparable to the numbers of BrdU -positive hepatocytes in healthy mouse liver (day À 1, n= 4 ). Statistical analysis using Mann -Whitney U test revealed that the differences in the numbers of BrdU -positive hepatocytes determined at days 2 and 4 after damage are not significant. These results show that AFP -specific vaccination does not interfere with hepatocyte proliferation after chemical liver damage in DBA /2 mice. Figure 4C demonstrates AFP expression in regenerating mouse liver after chemical damage with carbon tetrachloride. Two and 4 days after liver damage, AFPexpressing hepatocytes in the perinecrotic areas on the actual borders of necrosis could be detected. Nine days after damage, AFP -expressing cells could, like in normal liver ( day À 1), no longer be detected.
In experiments using C57BL / 6 mice, we could detect significantly more BrdU -labelled hepatocytes in mice vaccinated with AFP -expressing plasmid DNA (275 ± 68, n = 4) compared to mice vaccinated with control plasmid (91±37, n= 6 ) at day 4 after carbon tetrachloride injection ( data not shown ). But at the end of the regeneration period, livers have been completely regenerated in both groups of C57BL / 6 mice.
Discussion
Prophylactic AFP -specific vaccination of cirrhotic patients at high risk to develop HCC may be a useful tool to prevent the growth of AFP -positive liver cancer. Therefore, our aim was to investigate the use of AFP -specific DNA vaccination for the prevention of AFP -expressing tumors in the mouse model. In our experiments, DBA /2 mice were used, which express under normal conditions comparably low amounts of AFP and therefore are likely displaying lower tolerance towards AFP. 26 We could show that a prophylactic DNA vaccination with AFP -expressing plasmid DNA protects DBA /2 mice from growth of subcutaneous AFP -expressing tumor cells ( Fig 2 ) . Four weeks after tumor challenge, 62.5% of AFPvaccinated mice had been protected from growth of AFPpositive P815 tumors, whereas only 16.7% of mice vaccinated with control plasmid had been protected from growth of these tumor cells (P=.03). By Kaplan -Meier survival analysis, it was shown in a second set of experiments that mice that have been vaccinated with AFPexpressing plasmid DNA had a longer survival after challenge with a high dose of AFP -expressing tumor cells, which was, however, not significantly different from mice that have been vaccinated with control plasmid ( Fig 3 ) . Interestingly, we could not detect any tumor rejection in mice that had not received plasmid DNA injection (data not shown ). In contrast, injection of either AFP -expressing or control plasmid led to unspecific tumor rejection in at least some animals of the control groups ( groups II -IV ). This unspecific tumor cell rejection is likely to be caused by the immunostimulatory effect of bacterial DNA or by other proteins expressed from the vaccination plasmid. 27 Cancer Gene Therapy AFP -specific DNA vaccination P Hanke et al
Vollmer et al 17 firstly showed a prophylactic effect of an AFP -specific DNA vaccination on the growth of AFPpositive tumor cells in C57BL /6 mice. In their experiments, only 7.4% of mice was fully protected from tumor growth; in the remaining animals, a prolonged time until tumors reached diameters of 10 mm was observed. In our experiments, mice were repeatedly immunized over a period of 2 months and, in addition, the muscles were pretreated with cardiotoxin. AFP is a self -antigen highly expressed right after birth when the T-cell repertoire is positively selected in the thymus and tolerance towards self -antigens is established. Therefore, more than one immunization may be necessary to break tolerance for AFP. Cardiotoxin treatment of the muscle before DNA injection has been shown to considerably enhance the immunogenic effect of DNA vaccination. 28 The selected mouse strain may also influence the success of a DNA vaccination. C57BL / 6 mice and DBA / 2 mice express different MHC class I haplotypes and therefore present a different set of AFP peptides to induce a T-cell response. It may be possible that the AFP sequence contains more immunogenic H -2 d -binding T-cell epitopes rather than H -2 b epitopes favouring an immune response in DBA /2 mice rather than C57BL /6 mice.
In contrast to our experiments, Grimm et al 18 examined rejection of established tumors by AFP -specific DNA vaccination in a therapeutic approach. Repeated vaccination with a plasmid encoding a secreted AFP and, in addition, plasmids expressing the cytokines IL -12, IL -18, and GM -CSF led to rejection of established Hepa 1 -6 tumors in C57 /L mice. The AFP plasmid they used contained a truncated AFP fused to the leader sequence of a mouse immunoglobulin light chain. The resulting AFP fusion protein may have a different three -dimensional structure compared to wild -type AFP and may therefore lead to the presentation of cryptic epitopes that are more immunogenic than epitopes processed from the wild -type protein. This may break tolerance in a way that allows rejection of established tumors. The coinjection of cytokine -expressing plasmids, in addition to antigen-expressing plasmid, is very likely to support a T H 1-mediated cytotoxic AFP -specific immune response. 25 Even though we could show rejection of AFP -expressing tumor cells in vivo, we were not able to detect AFP -specific CTL from splenocytes in vitro. This phenomenon has been previously described for the melanoma -specific antigen, TRP -1. 29 Although not only rejection of TRP -1 -expressing tumor cells, but also an autoimmune reaction against nonmalignant TRP -1-expressing cells was shown in vivo, no cytotoxic TRP -1 -specific CTLs were detectable in vitro. It has been shown that CD4 -positive T H cells are able to mediate tumor rejection by induction of effector functions others than CD8 -positive CTLs. 30 Absent AFP -specific CTL activity may therefore implicate that AFP -specific tumor rejection has been caused by CTL -independent mechanisms in our vaccination approach. However, this hypothesis is not supported by data obtained in scid mice. We could not detect rejection of AFP -expressing tumor cells in scid mice vaccinated with AFP -expressing plasmid DNA. A tumor rejection mechanism independent of T lymphocytes could therefore be excluded. However, depletion experiments performed by Grimm et al 18 also indicate that CD4 -as well as CD8 -positive T lymphocytes are necessary for efficient tumor rejection. We favour the hypothesis that lacking cytotoxic activity in vitro may be a problem of insufficient in vivo activation or insufficient in vitro restimulation rather than absence of antigen-specific CTLs. The frequency of AFP -specific effector cells is supposed to be very low, and the affinity of their T cell receptors is likely to be weak because AFP is a self -antigen. Usage of a vaccination plasmid encoding either a cytoplasmic form of AFP or a truncated AFP, which is secreted due to a foreign secretion signal, led to the induction of up to 15% specific lysis in vitro. 18 These modified AFP sequences may prime T lymphocytes more efficiently than wild -type AFP, which was used in our experiments. We tried to optimize in vitro restimulation conditions in a way that we used syngeneic bone marrow -derived DCs, which were pulsed with concentrated AFP -containing tissue culture supernatant of the murine hepatoma cell line, Hepa 1-6. Although DCs are even able to stimulate naive T lymphocytes due to expression of costimulatory signals, they did not restimulate primed AFP -specific CTLs in vitro. 31 As murine AFP is not commercially available, we had to use concentrated Hepa 1-6 supernatant as a source for AFP. AFP has a half -life of only 24 hours in serum. 26 Therefore, it is not sure if sufficient amounts of AFP could have been endocytosed by the DCs in vitro. In addition, the presentation of peptides by MHC class I molecules may be not efficient enough due to exogenous supply of the antigenic protein. 32 It is therefore not surprising that a better restimulation was achieved by stimulator cells expressing the antigen endogenously. 18 The source of T lymphocytes tested for cytotoxicity might also be crucial. Vollmer et al detected AFP -specific CTLs from lymph nodes near the injection site of DNA. In these draining lymph nodes, the primary activation of naive AFP -specific T lymphocytes is likely to take place. 33 T lymphocytes derived from these lymph nodes might therefore be easier to restimulate in vitro.
TAAs are not exclusively expressed in malignant, but also in normal cells. It was shown in several transgenic mouse models that induction of an immune response against a TAA results in tumor rejection, but not in autoimmunity against normal cells expressing the same antigen. 34, 35 In contrast to this, a vaccination specific for the melanoma -associated TRP -1, which is also expressed in healthy keratinocytes, led to vitiligo in mice. 29, 36 AFP is not only expressed in HCC cells but also in regenerating hepatocytes. AFP -specific autoimmune reactions against AFP -expressing regenerating hepatocytes may be lifethreatening in patients suffering from hepatic failure. Therefore, we investigated the possible effects of an AFP -specific DNA vaccination on regenerating liver in mice with regard to a future application of this vaccination approach in humans. In mice, liver regeneration can be induced by injection of liver-damaging chemicals, i.e., carbon tetrachloride, or by partial hepatectomy ( PH ). 37, 38 We used a mouse liver regeneration model based on chemical liver injury, which more resembles chronic hepatitis than the PH model. Carbon tetrachloride causes a centrolobular necrotic liver damage that induces infiltration of inflammatory cells into the liver. Cirrhotic livers do also contain necrotic areas with infiltrating lymphocytes 39, 40 and it has to be evaluated whether in this situation AFP -specific lymphocytes destroy AFP -expressing regenerating hepatocytes and thus impair liver regeneration. In addition, it was shown in a transgenic mouse model that autoimmune reactions against a liver-specific model antigen were induced in the presence of additional inflammatory stimuli within the liver. 41 Such stimuli may be provided within cirrhotic liver tissue of patients. Over a regeneration period of 9 days after liver damage, we could not detect significant differences in the numbers of proliferating hepatocytes or the extent of remaining necrotic liver tissue in DBA /2 mice vaccinated with AFP -expressing plasmid compared to mice vaccinated with control plasmid (Fig 4, A and B ) . From this we conclude that liver regeneration even in the presence of infiltrating lymphocytes is not impaired in mice that had received an AFP -specific DNA vaccination. Immunohistochemical detection of AFP on liver sections demonstrates (Fig 4C ) that carbon tetrachloride -induced liver regeneration is accompanied by only a small number of AFP -expressing hepatocytes in defined areas of the regenerating liver. This may not reflect the situation in liver regeneration after hepatic failure in humans. Therefore, the influence of an AFP -specific vaccination on liver regeneration has to be further investigated in situations where more AFP -expressing hepatocytes are homogenously distributed throughout regenerating liver. In addition, the fact that CD8 -positive lymphocytes could be detected in regenerating liver does only indicate the existence of AFPspecific CTLs. The question of AFP -specific effector cells infiltrating the regenerating liver has to be addressed in further experiments. Geissler et al 42 recently investigated the influence of an AFP -specific DNA vaccination on liver regeneration induced by PH. They could show an autoimmune response directed against regenerating liver in mice vaccinated with AFP -expressing plasmid DNA. The autoimmune response was measured by increased serum ALT levels and by the presence of lymphatic infiltrates. Even though the appearance of the infiltrates correlated well with the AFP -specific cytotoxic immune response measured in spleen lymphocytes, there was also no evidence provided for the existence of AFP -specific CTLs in the liver. The observed autoimmune reaction was self -limited and merely prolonged the regeneration process. In contrast to these data, we could not detect a delayed regeneration process in our experimental setting. Although in C57BL /6 mice vaccinated with AFP -expressing plasmid DNA significantly more proliferating hepatocytes at day 4 after chemical liver injury were detected, the overall regeneration period was not prolonged.
Our results not only provide evidence for the efficiency of an AFP -specific DNA vaccination in terms of tumor rejection, but also show data ruling out possible negative effects on the physiologically important liver regeneration in mice. This may represent the basis for a clinical trial to prophylactically vaccinate patients at high risk to develop HCC.
